Active, Not Recruiting
Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT03763162
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States